Corvus Pharmaceuticals(CRVS) - 2024 Q2 - Earnings Call Presentation

Corvus Corporate Presentation August 2024 Focus on ITK Inhibitors with Broad Opportunities in Cancer & Immune Diseases Forward-Looking Statements / Safe Harbor 2 This presentation and the accompanying oral presentation contain "forward‐looking" statements, including statements related to the potential safety and efficacy of soquelitinib, ciforadenant and mupadolimab; the Company's ability and Angel Pharmaceutical's ability to develop and advance product candidates into and successfully complete preclinical ...